BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 21346614)

  • 21. Plasma oxytocin changes and anti-obsessive response during serotonin reuptake inhibitor treatment: a placebo controlled study.
    Humble MB; Uvnäs-Moberg K; Engström I; Bejerot S
    BMC Psychiatry; 2013 Dec; 13():344. PubMed ID: 24359174
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD).
    Haghighi M; Jahangard L; Mohammad-Beigi H; Bajoghli H; Hafezian H; Rahimi A; Afshar H; Holsboer-Trachsler E; Brand S
    Psychopharmacology (Berl); 2013 Aug; 228(4):633-40. PubMed ID: 23525525
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Pigott TA; Seay SM
    J Clin Psychiatry; 1999 Feb; 60(2):101-6. PubMed ID: 10084636
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study.
    Kordon A; Wahl K; Koch N; Zurowski B; Anlauf M; Vielhaber K; Kahl KG; Broocks A; Voderholzer U; Hohagen F
    J Clin Psychopharmacol; 2008 Oct; 28(5):550-4. PubMed ID: 18794652
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aripiprazole augmentation of clomipramine-refractory obsessive-compulsive disorder.
    Friedman S; Abdallah TA; Oumaya M; Rouillon F; Guelfi JD
    J Clin Psychiatry; 2007 Jun; 68(6):972-3. PubMed ID: 17592930
    [No Abstract]   [Full Text] [Related]  

  • 26. A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorder.
    Simpson HB; Foa EB; Liebowitz MR; Ledley DR; Huppert JD; Cahill S; Vermes D; Schmidt AB; Hembree E; Franklin M; Campeas R; Hahn CG; Petkova E
    Am J Psychiatry; 2008 May; 165(5):621-30. PubMed ID: 18316422
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
    Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L
    Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravenous Clomipramine for Treatment-Resistant Obsessive-Compulsive Disorder.
    Karameh WK; Khani M
    Int J Neuropsychopharmacol; 2015 Jul; 19(2):. PubMed ID: 26221004
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study.
    Li X; May RS; Tolbert LC; Jackson WT; Flournoy JM; Baxter LR
    J Clin Psychiatry; 2005 Jun; 66(6):736-43. PubMed ID: 15960567
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors.
    Denys D; de Geus F; van Megen HJ; Westenberg HG
    J Clin Psychiatry; 2004 Aug; 65(8):1040-8. PubMed ID: 15323587
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder.
    Foa EB; Liebowitz MR; Kozak MJ; Davies S; Campeas R; Franklin ME; Huppert JD; Kjernisted K; Rowan V; Schmidt AB; Simpson HB; Tu X
    Am J Psychiatry; 2005 Jan; 162(1):151-61. PubMed ID: 15625214
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transcutaneous electrical acupoint stimulation as an adjunct therapy for obsessive-compulsive disorder: A randomized controlled study.
    Feng B; Zhang ZJ; Zhu RM; Yuan GZ; Luo LY; McAlonan GM; Xu FZ; Chen J; Liu LY; Lv YY; Wong HK; Zhang Y; Zhu LX
    J Psychiatr Res; 2016 Sep; 80():30-37. PubMed ID: 27281260
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quetiapine augmentation of serotonin reuptake inhibitors in treatment-refractory obsessive-compulsive disorder: is response to treatment predictable?
    Carey PD; Lochner C; Kidd M; Van Ameringen M; Stein DJ; Denys D
    Int Clin Psychopharmacol; 2012 Nov; 27(6):321-5. PubMed ID: 22859064
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination of clomipramine and nortriptyline in the treatment of obsessive-compulsive disorder: a double-blind, placebo-controlled trial.
    Noorbala AA; Hosseini SH; Mohammadi MR; Akhondzadeh S
    J Clin Pharm Ther; 1998 Apr; 23(2):155-9. PubMed ID: 9786103
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparative, single-blind, randomized study on quetiapine and aripiperazole augmentation in treatment of selective serotonin reuptake inhibitor refractory obsessive-compulsive disorder.
    Talaei A; Hosseini FF; Aghili Z; Akhondzadeh S; Asadpour E; Mehramiz NJ; Forouzanfar F
    Can J Physiol Pharmacol; 2020 Apr; 98(4):236-242. PubMed ID: 32228235
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term pharmacotherapy of obsessive-compulsive disorder: a double-blind controlled study.
    Mundo E; Bareggi SR; Pirola R; Bellodi L; Smeraldi E
    J Clin Psychopharmacol; 1997 Feb; 17(1):4-10. PubMed ID: 9004050
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder.
    Koran LM; Aboujaoude E; Gamel NN
    J Clin Psychiatry; 2009 Nov; 70(11):1530-5. PubMed ID: 19573497
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review.
    Piccinelli M; Pini S; Bellantuono C; Wilkinson G
    Br J Psychiatry; 1995 Apr; 166(4):424-43. PubMed ID: 7795913
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial.
    Bystritsky A; Ackerman DL; Rosen RM; Vapnik T; Gorbis E; Maidment KM; Saxena S
    J Clin Psychiatry; 2004 Apr; 65(4):565-8. PubMed ID: 15119922
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aripiprazole augmentation in 39 adolescents with medication-resistant obsessive-compulsive disorder.
    Masi G; Pfanner C; Millepiedi S; Berloffa S
    J Clin Psychopharmacol; 2010 Dec; 30(6):688-93. PubMed ID: 21105283
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.